Who
Gayle A. Crowell
Director
Company insider
Files Form 4 as: Director, Pliant Therapeutics; Director, Hercules Capital; Director, Envestnet; Director, Yodlee; Director, Scientific Learning.
In numbers
- Trades disclosed
- 130
- Buys
- 9
- Sells
- 26
- Bought
- $930K
- Sold
- $997K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 2 Nov 2010
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $105K7,317 at $14.35 | filing |
| 26 Mar 2026filed 30 Mar 2026 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $105K7,317 at $14.35 | filing |
| 23 Feb 2026filed 25 Feb 2026 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $100K6,600 at $15.20 | filing |
| 23 Feb 2026filed 25 Feb 2026 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $100K6,600 at $15.20 | filing |
| 3 Nov 2025filed 4 Nov 2025 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $107K6,000 at $17.77 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 8 May 2025filed 9 May 2025 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $105K5,999 at $17.49 | filing |
| 25 Nov 2024filed 25 Nov 2024 | Envestnetoption or derivative | SEC FORM 4 Code D | —1,745 | filing |
| 25 Nov 2024filed 25 Nov 2024 | Envestnet | SEC FORM 4 Code D | $1.1M17,075 at $63.15 | filing |
| 25 Nov 2024filed 25 Nov 2024 | Envestnet | SEC FORM 4 Code D | $243K3,852 at $63.15 | filing |
| 6 Aug 2024filed 8 Aug 2024 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $105K5,790 at $18.06 | filing |
| 25 Jun 2024filed 26 Jun 2024 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Bought | $14K701.6 at $20.05 | filing |
| 20 Jun 2024filed 24 Jun 2024 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Code A | $60K3,030 at $19.80 | filing |
| 13 Jun 2024filed 17 Jun 2024 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,764 at $0.00 | filing |
| 29 Feb 2024filed 4 Mar 2024 | Envestnet | SEC FORM 4 Code A | —3,987 at $0.00 | filing |
| 22 Nov 2023filed 27 Nov 2023 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Code A | $2,365149 at $15.87 | filing |
| 22 Nov 2023filed 27 Nov 2023 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Code A | $17K1,051 at $15.72 | filing |
| 8 Sep 2023filed 11 Sep 2023 | HTGC Hercules CapitalCapital Markets & Asset Management | SEC FORM 4 Code A | $90K5,656 at $15.90 | filing |
News
Hercules Capital (NYSE:HTGC) vs. ONEX (OTCMKTS:ONEXF) Financial ReviewHTGC · dailypolitical.com · 18 Oct 2026Head-To-Head Analysis: Hercules Capital (NYSE:HTGC) & ONEX (OTCMKTS:ONEXF)HTGC · tickerreport.com · 18 Oct 2026Moelis & Company (NYSE:MC) vs. Hercules Capital (NYSE:HTGC) Financial ReviewHTGC · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Gayle A. Crowell; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.